TG Therapeutics | TGTX - Current Assets


TG Therapeutics reported $599.76M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Alaunos Therapeutics USD 2.68M 1.05M Sep/2025
Amgen USD 29.06B 1.17B Dec/2025
Ardelyx USD 367.98M 16.42M Sep/2025
Arrowhead Research USD 1.17B 223.75M Dec/2025
Bayer EUR 32.88B 873M Sep/2025
Biogen USD 8.97B 37.5M Dec/2025
Corcept Therapeutics USD 485.46M 55.67M Dec/2025
Curis USD 14.42M 10.39M Jun/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
Infinity Pharmaceuticals USD 19.91M 8.46M Jun/2023
J&J USD 55.62B 1.01B Dec/2025
Karyopharm Therapeutics USD 89.75M 8.12M Sep/2025
Novartis USD 28.2B 2.26B Sep/2025
Novavax USD 974.59M 55.08M Sep/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
TG Therapeutics USD 599.76M 64.2M Sep/2025
Verastem USD 124.7M 29.74M Mar/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025